OBR OncologyTwo “Homerun” Trials Expected to Change Standard for Advanced, Recurrent Endometrial Cancer

Results from the RUBY trial of dostarlimab and the GY018/Keynote-068 of pembrolizumab were presented at the 2023 SGO Annual Meeting on Women’s Cancer in March and were simultaneously published in The New England Journal of Medicine. The studies examined the efficacy and safety of the medications in all individuals and those with mismatch repair deficient (dMMR) illness. Each trial examined a separate PD-1 inhibitor, pembrolizumab or dostarlimab, in combination with chemotherapy in patients with advanced or recurrent endometrial cancer. In individuals with dMMR illness, both medications lowered the chance of disease progression or death by roughly 70%.